PRDM16 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain PRDM16 status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [4].

PRDM16 is an inclusion criterion in 3 clinical trials for secondary acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain PRDM16 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

PRDM16 is an inclusion criterion in 2 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain PRDM16 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PRDM16 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PRDM16 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].